Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
75°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Akero Therapeutics
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
December 18, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
November 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 08, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
October 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
October 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
October 09, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
October 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
August 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
August 28, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 11, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
June 23, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
June 05, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
June 01, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
May 16, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
March 29, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 17, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
January 10, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
December 21, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
December 08, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 10, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
November 07, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 04, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022
From
Akero Therapeutics
Via
GlobeNewswire
Tickers
AKRO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.